<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04751344</url>
  </required_header>
  <id_info>
    <org_study_id>101719</org_study_id>
    <nct_id>NCT04751344</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine Versus Bupivacaine Plain for Operative Pain Management of Forefoot Surgery</brief_title>
  <official_title>RANDOMIZED CONTROLLED TRIAL COMPARING LIPOSOMAL BUPIVACAINE VERSUS BUPIVACAINE HCL FOR POSTOPERATIVE MANAGEMENT OF FOREFOOT SURGERY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandra Black</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lenox Hill Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, controlled single-blinded trial comparing liposomal bupivacaine with&#xD;
      bupivacaine HCl for postoperative management. Upon completion of the forefoot procedure in&#xD;
      the operative room the subject will be entered into the randomization system which will&#xD;
      specify whether to inject 10cc (5mg/mL) of bupivacaine HCl or 8cc (13.3 mg/mL) liposomal&#xD;
      bupivacaine, both considered routine care procedure. Thereafter, postoperative pain will be&#xD;
      assessed and measured using a Visual Analog Scale (VAS) scoring scale post-operatively at 2&#xD;
      hours, 24 hours, 48 hours and 72 hours. In addition, the amount of oral morphine equivalents&#xD;
      (OME) required postoperatively and time to first use of OME will be measured. Our hypothesis&#xD;
      is that patients who received liposomal bupivacaine will have less post-operative pain and&#xD;
      require less OMEs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Data will be encrypted using BRMS</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of liposomal bupivacaine on postoperative pain control</measure>
    <time_frame>The study will last 72 hours after the elective procedure.</time_frame>
    <description>VAS scores, which measure the intensity of pain on a scale of 1 to 10, will be collected at 2, 24, 48 and 72 hours post-operatively in order to assess therapeutic effect of local anesthetic medication for postoperative pain control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of liposomal bupivacaine on opioid use</measure>
    <time_frame>The study will last 72 hours after the elective procedure.</time_frame>
    <description>We will quantify opioid use post-operatively by collecting data on total opioid consumption and time to first use of the opioid post-operatively by the patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liposomal Bupivacaine</condition>
  <condition>Postoperative Pain</condition>
  <condition>Forefoot Surgery</condition>
  <condition>Opioid Use</condition>
  <condition>Bunion</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The liposomal bupivacaine study arm will receive 8cc (13.3 mg/mL) liposomal bupivacaine via intravenous route at the completion of the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Bupivacaine HCl study arm will receive 10cc (5mg/mL) of bupivacaine HCl via intravenous route at the completion of the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 8cc of liposomal bupivacaine (13.3mg/mL) will be injected around the surgical site.</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl</intervention_name>
    <description>Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 10cc of bupivacaine HCl (5mg/mL) will be injected around the surgical site.</description>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed and dated informed consent form&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Male or female, greater than 18 years of age&#xD;
&#xD;
          -  ASA Class I or II&#xD;
&#xD;
          -  Ability to take oral medication in order to assess the patient's opioid regimen&#xD;
             postoperatively&#xD;
&#xD;
          -  Forefoot surgery, including bunionectomy +/- digital surgery&#xD;
&#xD;
          -  For females of reproductive potential: hCG levels will be determined during the&#xD;
             pre-operative period. Females of childbearing age require a hCG level below 5mIU/mL in&#xD;
             order to participate in the study. hCG levels above 25 mIU/mL is considered positive&#xD;
             for pregnancy and, as a result, the patient will not be considered eligible for&#xD;
             inclusion in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic users of opioids, use for greater than 14 days in the last 3 months or&#xD;
             nonopioid pain medications for more than 5 times per week&#xD;
&#xD;
          -  Prescription for SSRIs, gabapentin, duloxetine within 3 days of surgery&#xD;
&#xD;
          -  Systemic glucocorticoids within 1 month of study enrollment&#xD;
&#xD;
          -  History of hepatitis&#xD;
&#xD;
          -  History of peripheral vascular disease&#xD;
&#xD;
          -  History of diabetes mellitus type 1 or 2&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Allergic to opioids&#xD;
&#xD;
          -  Known allergic reactions to components of the bupivacaine injectable or other amide&#xD;
             anesthetics; the allergen may involve preservative compounds such as methylparaben&#xD;
             used in the preparation of amide-type agents are metabolized to PABA&#xD;
&#xD;
          -  BMI &gt; 40&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot Hershman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Black, DPM</last_name>
    <phone>212-570-9300</phone>
    <email>alextblack@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sariah Ramoutarpersaud, MD</last_name>
    <phone>718-869-3517</phone>
    <email>sramoutarp@northwell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Manhattan Eyes Ears and Throat Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elliot Hershman, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Lenox Hill Hospital</investigator_affiliation>
    <investigator_full_name>Alexandra Black</investigator_full_name>
    <investigator_title>DPM</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bunion</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

